Huaqing Pharmaceutical (688302.SH): The final analysis results of the clinical Phase IIa trial of the drug HP515 for treating metabolic associated fatty liver disease (MAFLD) have been achieved.

H-Brave Pharmaceutical (688302.SH) announced that the final analysis of the Phase IIa clinical trial of HP515 tablets, a class 1 innovative drug developed by the company for the treatment of metabolic-associated fatty liver disease (MASH, formerly known as non-alcoholic fatty liver disease (NASH)), has reached the primary and key secondary endpoints. The trial results indicate that HP515 tablets can significantly improve liver fat metabolism, as well as improve abnormalities in blood lipids, and overall demonstrate good safety. The final analysis of the trial meeting the primary and key secondary endpoints will not have a significant impact on the company's recent operating performance.